0000891293-23-000001.txt : 20230103
0000891293-23-000001.hdr.sgml : 20230103
20230103183652
ACCESSION NUMBER: 0000891293-23-000001
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221229
FILED AS OF DATE: 20230103
DATE AS OF CHANGE: 20230103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KIRSKE DAVID
CENTRAL INDEX KEY: 0001276750
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 23503815
MAIL ADDRESS:
STREET 1: C/O CTI BIOPHARMA CORP.
STREET 2: 3101 WESTERN AVE., SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2022-12-29
0
0000891293
CTI BIOPHARMA CORP
CTIC
0001276750
KIRSKE DAVID
C/O CTI BIOPHARMA CORP.
3101 WESTERN AVE., SUITE 800
SEATTLE
WA
98121
0
1
0
0
EVP, Chief Financial Officer
common stock
2022-12-29
4
M
0
13174
0.9489
A
30087
D
common stock
2022-12-29
4
S
0
13174
6
D
16913
D
common stock
2022-12-30
4
A
0
214
5.1085
A
17127
D
common stock
2022-12-30
4
M
0
12000
0.9489
A
29127
D
common stock
2022-12-30
4
S
0
12000
6
D
17127
D
common stock
2022-12-30
4
M
0
800
0.9489
A
17927
D
common stock
2022-12-30
4
S
0
800
6.005
D
17127
D
common stock
2022-12-30
4
M
0
1047
0.9489
A
18174
D
common stock
2022-12-30
4
S
0
1047
6.01
D
17127
D
common stock
2023-01-03
4
M
0
27021
0.9489
A
44148
D
common stock
2023-01-03
4
S
0
27021
6.011
D
17127
D
Non-Qualified Stock Option (right to buy)
0.9489
2022-12-29
4
M
0
13174
0
D
2029-02-19
Common Stock
13174
311084
D
Non-Qualified Stock Option (right to buy)
0.9489
2022-12-30
4
M
0
12000
0
D
2029-02-19
Common Stock
12000
299084
D
Non-Qualified Stock Option (right to buy)
0.9489
2022-12-30
4
M
0
800
0
D
2029-02-19
Common Stock
800
298284
D
Non-Qualified Stock Option (right to buy)
0.9489
2022-12-30
4
M
0
1047
0
D
2029-02-19
Common Stock
1047
297237
D
Non-Qualified Stock Option (right to buy)
0.9489
2023-01-03
4
M
0
27021
0
D
2029-02-19
Common Stock
27021
270216
D
This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.
David Kirske
2023-01-03